<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491242</url>
  </required_header>
  <id_info>
    <org_study_id>Dolbi</org_study_id>
    <nct_id>NCT02491242</nct_id>
  </id_info>
  <brief_title>Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression</brief_title>
  <acronym>DOLBI</acronym>
  <official_title>The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion para el Estudio de las Enfermedades Infecciosas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociacion para el Estudio de las Enfermedades Infecciosas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the efficacy and safety, and evolution of causes
      leading to change, of dual therapies based in Dolutegravir in patients requiring a change of
      virologically effective antiretroviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the high rate of virological suppression and low risk of toxicity, HIV-infected
      patients continue to need new antiretroviral strategies, such as dual therapies, because of
      different end-organ involvement (kidney, bone, cardiovascular..), intolerance or toxicity. To
      date, only a protease inhibitor (PI)-based regimen was able to permit the use of dual
      therapies (two antiretrovirals), especially in case of patients with history of virological
      failure to other regimens. However, the recent license of Dolutegravir, a integrase inhibitor
      with high genetic barrier, could help to clinicians to manage patients with intolerance or
      toxicity to nucleoside analogues without putting in risk virological suppression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Efficacy, measured as maintenance of virological suppression, after switching to a dolutegravir-based dual therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of patients remaining with HIV RNA level below 50 copies/ml, according to a missing=failure criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety according to DAIDS grade events 2009 of dual therapy based in dolutegravir</measure>
    <time_frame>12 months</time_frame>
    <description>To collect adverse events (according to DAIDS grade events, 2009) and rate of discontinuation related with adverse events, of dual therapy after switching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of causes leading to switch the previous regimen</measure>
    <time_frame>12 months</time_frame>
    <description>Evolution of causes de change: glomerular filtration rate during evolution, tubular dysfunction (proteinuria, phosphaturia, glycosuria, uricosuria),bone mineral density by DXA (dual X-ray absorptiometry), lipid disorders, adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy, measured as maintenance of virological suppression, of different dual therapies with dolutegravir</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of efficacy (HIV RNA level &lt; 50 c/ml) of the different dolutegravir-based dual therapies, according to accompanying drug (non nucleoside, especially rilpivirine), protease inhibitors (darunavir boosted with ritonavir or cobicistat), or nucleoside analogues (lamivudine).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of virological suppression in patients with previous failure to more than 2 families of antiretroviral drugs</measure>
    <time_frame>12 months</time_frame>
    <description>Effect of extended previous failure, or mutations in the transcriptase and protease gene, in the rate of virological suppression in dolutegravir-based dual therapies</description>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dolutegravir in a dual therapy regimen</intervention_name>
    <description>None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients who had initiate a dolutegravir-based dual therapy because of
        intolerance or toxicity to nucleoside analogues
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years

          -  Receiving a virologically effective antiretroviral regimen

          -  Switching to a dual therapy based in dolutegravir because of intolerance or toxicity
             to nucleoside analogues

        Exclusion Criteria:

          -  Pregnant women

          -  Receiving other investigational drugs

          -  Recent diagnosis of opportunistic infection (&lt; 1 month)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Casado, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramon y Cajal Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose L Casado, MD, PhD</last_name>
    <phone>34913368672</phone>
    <email>jcasado.hrc@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Casado, MD, PhD</last_name>
      <phone>34913368672</phone>
      <email>jcasado.hrc@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Sara Bañón, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Diaz de Santiago, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Moreno, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago Moreno, Md PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asociacion para el Estudio de las Enfermedades Infecciosas</investigator_affiliation>
    <investigator_full_name>Jose L. Casado</investigator_full_name>
    <investigator_title>Physician, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>dolutegravir</keyword>
  <keyword>intolerance</keyword>
  <keyword>dual therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

